There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Basimglurant in Children, Adolescents, and Young Adults With TSC
NCT05059327
Recruiting
The study intends to show that basimglurant provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
Gender:
All
Ages:
Between 5 years and 30 years
Trial Updated:
06/12/2024
Locations: David Geffen School of Medicine at UCLA (Site #: 101), Los Angeles, California
Conditions: Tuberous Sclerosis Complex
Register for Updates
RISE (Reinvent, Integrate, Strengthen, Expand) Self-Management Program for Cancer Survivors: A Feasibility Study
NCT05128838
Recruiting
This is a prospective feasibility study using a convenience sample of cancer survivors from Cedars-Sinai and its surrounding catchment area. As this study will be primarily focused on optimization of the RISE (Re-invent, Integrate, Strengthen, Expand) protocol, there will be no control group or randomization of participants. The RISE intervention is informed by the principles of Lifestyle Redesign, an occupational therapy-based therapeutic technique focused on measurable, individually-tailored,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cancer, Survivorship
Register for Updates
Personalized Self-Management Training Compared to Standardized Self-Management Training in Colorectal Cancer Patients.
NCT05984589
Recruiting
This is a Phase 2 prospective, randomized, controlled, double-arm study to assess personalized self-management training (PSMT) intervention efficacy and patient experiences compared to standardized self-management training (SSMT). A total of 120 colorectal cancer (CRC) patients will be enrolled and randomized 1:1 to complete a 6-week self-management training program (either PSMT or SSMT) to be carried out by licensed occupational therapists with doctoral training. This study aims to examine whe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Colorectal Cancer, Healthy Lifestyle, Behavior, Health, Health Behavior
Register for Updates
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
NCT05459129
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received sy... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Lurbinectedin in FET-Fused Tumors
NCT05918640
Recruiting
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Gender:
All
Ages:
10 years and above
Trial Updated:
06/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Register for Updates
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Site US10040, Los Angeles, California +1 locations
Conditions: Prostate Cancer
Register for Updates
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
NCT05440786
Recruiting
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
06/11/2024
Locations: The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles, California
Conditions: Sarcoma, Ewing, Neoplasm Metastasis
Register for Updates
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399
Recruiting
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/11/2024
Locations: The Angeles Clinic and Research Institute, Los Angeles, California
Conditions: Melanoma
Register for Updates
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Gender:
All
Ages:
Between 18 years and 123 years
Trial Updated:
06/11/2024
Locations: Research Site, Los Angeles, California
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Register for Updates
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
NCT05443126
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California
Conditions: Advanced Solid Tumor
Register for Updates
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03075696
Recruiting
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-to-human study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant do... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
NCT04979338
Recruiting
This study will compare the current standard-of-care pain treatment regimen options that are available to patients who undergo gender-affirming surgery. The purpose of this research is to determine if any of these options are more (versus less) effective than the others to manage surgery related pain, after surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Cedars-Sinai Medical Center - North and South Towers, Los Angeles, California
Conditions: Gender Dysphoria
Register for Updates